Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UPC: A review of 2025 and what to expect in 2026

31 December 2025 As the Unified Patent Court continues in its third year, there are inevitable issues that continue to arise as it grows as a jurisdiction, writes Darren Smyth of EIP.

Europe

Mental health in IP: ‘We have a clear picture of the problem’

30 December 2025 The Life in the Law 2025 report sheds light on the mental health challenges faced by legal professionals, revealing the links between wellbeing, inclusion and modern working practices. IP Inclusive’s Andrea Brewster explores how the findings offer clear guidance for meaningful change.

Europe

From Edwards to Insulet: Three key medical device cases of 2025

29 December 2025 Edwards v Meril, Teva and the FTC, and modified jury verdicts—lawyers from WilmerHale provide a review of the key cases of the year and their implications.

More features

Regeneron v Alvotech: The big impact

Beyond traditional IP: A comprehensive AI strategy for life sciences

Prosecuting bispecific antibody patents: A cookbook for patent chefs

Novo Nordisk ramps up semaglutide defence as generics lurk

Novo Nordisk India strategy suffers semaglutide patent setback

EU Pharma Package hits the final stretch—but can negotiators agree?

The clinical trial dilemma: Navigating European practice

Still Unsettling: The uncertain landscape for discretionary denial

Biologics in India: bridging the gap

More on this story

Editor's picks

Editor's picks

More features